IntelliCell BioSciences, Inc., of New York City, announced the filing of a patent application for a new research technique for regenerative medicine. The provisional patent expands the field of cellular therapy and research in adipose stromal vascular fraction (SVF).
Company officials say that for the first time SVF will be harvested from non-living adipose tissue for research and clinical purposes. They note that, previously, only surgeons performing liposuction could supply samples of lipoaspirate cells which were then processed to yield SVF.
According to IntelliCell’s Chairman and CEO Steven Victor, M.D., in the July 23 news release, “This will be transformational in the field of adipose stromal vascular fraction. SVF cells from adipose tissue will soon be readily available for researchers and institutions around the world to study and advance the field of cellular therapy with SVFs.”
Robert Sexauer, Vice-President of Clinical Development, stated, “Much as organ donation has saved many, many lives, this process can lead to the development of new lifesaving treatments.” He added, “The future of medicine will reach an exciting stage when SVF will be stored in all major hospitals, similar to blood for transfusions, and these cells will be readily available to treat patients for a multitude of injuries and ailments (i.e., orthopaedic, post myocardial infarction etc.). We believe this discovery will change the way patients are treated.”
IntelliCell BioSciences is a regenerative medicine company focused on using adult autologous vascular cells (SVC’s) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed a method to separate adult autologous vascular cells from adipose tissue without the use of enzymes.
